HIFU for Focal Ablation of Prostate Tissue: An Observational Study

Description

The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.

Conditions

Prostate Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.

High-Intensity Focused Ultrasound for Focal Ablation of Prostate Tissue: An Observational Study of Multiparametric MRI and Ultrasound Fusion Imaging for Guidance

HIFU for Focal Ablation of Prostate Tissue: An Observational Study

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California, Los Angeles, Los Angeles, California, United States, 90095

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age 40 years to 85 years
  • 2. Subject has elected or already undergone HIFU therapy as their standard of care treatment methodand declined alternative treatment (active surveillance, radical prostatectomy, radiation therapy, cryosurgery and hormone therapy)
  • 3. PSA ≤ 20
  • 4. Prostate volume of ≤ 70 cc
  • 5. Ability to complete informed consent form
  • 1. Prior treatment for prostate cancer (with the exception of androgen deprivation therapy)
  • 2. Medical contraindication to follow-up mpMRI or prostate biopsy
  • 3. Unable to tolerate general or regional anesthesia
  • 4. Positive bone scan (only if bone scan has been done or clinically indicated. Bone scan does not need to be performed for study eligibility determination.)

Ages Eligible for Study

40 Years to 85 Years

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Los Angeles,

Leonard Marks, MD, PRINCIPAL_INVESTIGATOR, University of California, Los Angeles

Study Record Dates

2028-01-31